The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
The D 2 /D 3 agonist radioligand [ 11 C]-(+)-PHNO is currently the most suitable D 3 imaging agent available, despite its limited selectivity for the D 3 over the D 2 . Given the collocation of D 2 and D 3 receptors, and generally higher densities of D 2 , the separation of D 2 and D 3 information from [ 11...
The dopamine D 3 receptor is thought to be a potential target for treating compulsive disorders such as drug addiction and obesity. Here, we used functional Magnetic Resonance Imaging (fMRI) to investigate the effects the selective dopamine D 3 receptor antagonist GSK598809 on brain activation to food images in a sample of overweight and obese binge-eating subjects. Consistent with...
Dopamine D 3 receptors are involved in the pathophysiology of several neuropsychiatric conditions. [ 11 C]-(+)-PHNO is a radiolabeled D 2 and D 3 agonist, suitable for imaging the agonist binding sites (denoted D 2HIGH and D 3 ) of these receptors with positron emission tomography (PET). PET studies in nonhuman primates documented that, in vivo, [ ...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.